GlassScriptPhysician profile
Merri Earl
NPI 1437573938
$3,174.75
in general payments reported to CMS, 2019-2025
27 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $810 · 2022: $695 · 2023: $697 · 2024: $517 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,669.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.55 | 2022-2025 | |
| Abbott Laboratories | $517.76 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $408.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $258.49 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $193.88 | 2021-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $133.17 | 2021-2025 | Trintellix |
| Eisai INC. | $128.33 | 2021-2022 | |
| Astellas Pharma US INC | $111.42 | 2021-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.24 | 2021-2024 | Jardiance |
| Amgen INC. | $105.80 | 2021 | |
| Pfizer INC. | $85.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $80.65 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $78.60 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.46 | 2023 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $39.22 | 2024-2025 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $38.99 | 2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $37.93 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Exact Sciences Corporation | $32.43 | 2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $30.31 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.10 | 2023 | |
| Inspire Medical Systems, INC. | $23.69 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $21.91 | 2025 | Givlaari |
| Sanofi-Aventis U.S. LLC | $18.04 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.23 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $14.65 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $13.84 | 2022 | |
| Dexcom, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merri Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.